Adipose-derived mesenchymal stem cells improved acute renal failure induced by ischemia-reperfusion injury: Focusing on toll-like receptor 4 activity and endoplasmic reticulum stress response.
Hafazeh L., Kadkhodaee M., Seifi B., Akhondzadeh F., Azedi F., Noori H.
Animal Study on Chronic Kidney Disease, Acute Kidney Injury, published in J Physiol Biochem (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Physiol Biochem (2026)
- Country
- Spain
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42435285
- DOI
- 10.1007/s13105-026-01207-w
Abstract (original English)
This study evaluated the efficacy of adipose-derived mesenchymal stem cells (AD-MSCs) in reducing pathological alterations linked to acute kidney injury (AKI) caused by ischemia-reperfusion injury (IRI). In this study, 18 male rats were divided into three groups: Sham, IRI, and IRI + AD-MSC. IRI was induced by clamping the renal pedicles for 45 min, while the Sham group animals underwent the same surgical procedure without vascular clamping. In the IRI + AD-MSC groups, immediately after clamp removal, the animals received an intraperitoneal injection of 1 × 10⁶ AD-MSCs. To enable tracking, AD-MSCs were transfected with green fluorescent protein (GFP). The distribution of these labeled cells was examined at 24 and 48 h post-transplantation in three additional rats. Forty-eight hours after reperfusion, serum and kidney tissue samples were collected. The labeled AD-MSCs were more widely distributed in the injured kidney area of the IRI + AD-MSC group compared to the control group. In the group treated with AD-MSCs, there were notable reductions in serum blood urea nitrogen (BUN) and creatinine levels (P < 0.001), along with improvements in renal tissue damage and oxidative stress (P < 0.01). Additionally, the IRI + AD-MSC group showed significant decreases in toll-like receptor-4 (TLR4) protein levels (P < 0.01) and pro-inflammatory factors (P < 0.001), as well as reduced levels o
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations